|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Loma Linda University |
| Information provided by: | Loma Linda University |
| ClinicalTrials.gov Identifier: | NCT00616850 |
Purpose
Total knee replacement is often associated with severe postoperative pain, especially in the first 24 hours. Patient controlled analgesia (PCA) and continuous femoral block with PCA are commonly used to treat postoperative pain after total knee arthroplasty. However, PCAs use opioids. Opioids are excellent painkillers but their use is hampered by side effects such as nausea, vomiting, bowel dysfunction, urinary retention, pruritus, sedation and respiratory depression. We propose to test the hypothesis that adding a low dose lidocaine infusion to PCAs will lower the amount of opioids that these patients receive, thereby improving patient safety while still providing adequate analgesia. In addition, continuous femoral block has been shown to provide superior postoperative pain control when compared to morphine PCA. Therefore, postoperative pain levels of study subjects will be compared to those subjects who receive a combination of a continuous femoral block catheter with a PCA.
| Condition | Intervention |
|
Total Knee Arthroplasty |
Procedure: Continuous femoral catheter block Drug: Lidocaine Other: Preservative free normal saline |
| MedlinePlus related topics: | Knee Replacement Nausea and Vomiting |
| ChemIDplus related topics: | Sodium chloride Ropivacaine Ropivacaine Hydrochloride Ropivacaine monohydrochloride Lidocaine Epinephrine Epinephrine bitartrate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Factorial Assignment, Safety/Efficacy Study |
| Official Title: | Treatment of Postoperative Pain After Total Knee Arthroplasty Using Intravenous Lidocaine Infusion in Combination With Patient Controlled Analgesia Versus Continuous Femoral Block Catheter in Combination With Patient Controlled Analgesia: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Study. |
| Estimated Enrollment: | 99 |
| Study Start Date: | October 2007 |
| Estimated Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|
Group A: Active Comparator
Group A subjects will receive a continuous femoral block catheter and a Patient Controlled Analgesia (PCA).
|
Procedure: Continuous femoral catheter block
A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
|
|
Group B: Experimental
Group B subjects will receive a low dose lidocaine (1.33 mg/kg/hr) infusion and a Patient Controlled Analgesia.
|
Drug: Lidocaine
Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
|
|
Group C: Placebo Comparator
Group C subjects will receive placebo (preservative free normal saline) infusion and a Patient Controlled Analgesia.
|
Other: Preservative free normal saline
Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
|
Eligibility
| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |||||
| Loma Linda University Medical Center | Recruiting | ||||
| Loma Linda, California, United States, 92354 | |||||
| Contact: Pat Moore 909-558-8493 | |||||
| Sub-Investigator: Jonathan Kelling, M.D. | |||||
| Loma Linda University |
| Principal Investigator: | Michelle Schlunt, M.D. | Loma Linda University Medical Center |
More Information
| Responsible Party: | Loma Linda University Medical Center, Department of Anesthesia ( Michelle Schlunt, M.D. ) |
| Study ID Numbers: | 57175 |
| First Received: | February 4, 2008 |
| Last Updated: | August 13, 2008 |
| ClinicalTrials.gov Identifier: | NCT00616850 |
| Health Authority: | United States: Institutional Review Board |
|
|
|
|
|